Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target ...
Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status. Ryan Haumschild, PharmD, MS, MBA: As we start to transition ...
An overview of the PARAGON-HF trial with special consideration to the rationale behind the design, the cardiovascular end points, and the safety profile. John McMurray, MBChB: The most recent attempt ...
A device you might want with you in an avalanche; why heart failure with preserved ejection fraction may be seen as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback